Rhone-Poulenc Rorer has received a license for sparfloxacin in the UK and Switzerland for the treatment of respiratory tract infections.
The compound, developed in Europe by Rhone-DPC, a joint-venture between Japanese firm Dainippon and R-PR, was launched in France by Specia last September under the tradename Zagam. Launches in other European countries are scheduled through 1995 to the beginning of 1996. Additionally, the company expects to file a New Drug Application in the USA by the end of this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze